Skip to main content
Top
Published in: Indian Journal of Gastroenterology 3/2014

01-05-2014 | Original Article

Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis?

Authors: Waheed Abdelmonsef Mahmoud, Nadia Abdelaaty Abdelkader, Amal Mansor

Published in: Indian Journal of Gastroenterology | Issue 3/2014

Login to get access

Abstract

Purpose

This study aimed to determine whether serum levels of nitric oxide metabolites (nitrates and nitrites) correlate with renal dysfunction in patients with liver cirrhosis and, moreover, to assess nitric oxide metabolite (NOx) power for predicting hepatorenal syndrome (HRS) in such patients.

Methods

Among patients admitted to the Tropical Medicine Department, Ain Shams University Hospital, a total of 60 patients with chronic hepatitis C-related liver cirrhosis were included in this study. Patients were divided into three groups. Group I included 20 patients with compensated liver cirrhosis (CLC). Group II included 20 patients with decompensated liver cirrhosis (DLC). Group III included 20 patients with decompensated liver cirrhosis and HRS. Twenty healthy subjects with no clinical or laboratory evidence of liver disease were enrolled as a control group (group IV).

Results

Patients with HRS had a higher mean nitrite levels followed by DLC, then CLC, and then controls. The sensitivity and specificity of NO metabolites (nitrites) were 100 % and 93.3 %, respectively, with accuracy of 95 % at cutoff value of 387 μmol/L for diagnosing patients with HRS. There was a highly significant statistical difference between patients positive and negative for nitrites as regards renal profile (p = 0.000).

Conclusion

A strong relation between nitrite cutoff value and renal dysfunction in liver cirrhosis has been found. Also, patients with HRS had higher mean serum nitrite levels than decompensated liver cirrhosis or compensated liver cirrhosis, raising the possibility of using nitrate and nitrite levels as a predictor for HRS in HCV-related liver cirrhosis.
Literature
1.
go back to reference Gines P, Cardenás A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646–54.PubMedCrossRef Gines P, Cardenás A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646–54.PubMedCrossRef
2.
go back to reference Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–8.PubMedCentralPubMed Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–8.PubMedCentralPubMed
3.
go back to reference Parvu AE, Negrean V, Pleca-Manea L, et al. Nitric oxide in patients with chronic liver diseases. Rom J Gastroenterol. 2005;14:225–30.PubMed Parvu AE, Negrean V, Pleca-Manea L, et al. Nitric oxide in patients with chronic liver diseases. Rom J Gastroenterol. 2005;14:225–30.PubMed
4.
go back to reference Péron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol. 2005;100:2702–7.PubMedCrossRef Péron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol. 2005;100:2702–7.PubMedCrossRef
5.
go back to reference Coskun U, Ozenirler S, Sancak B, Bukan N. Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clin Chim Acta. 2001;306:127–32.PubMedCrossRef Coskun U, Ozenirler S, Sancak B, Bukan N. Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clin Chim Acta. 2001;306:127–32.PubMedCrossRef
6.
go back to reference Liu H, Gaskari SA, Lee SS. Cardiac and renal changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol. 2006;12:837–42.PubMed Liu H, Gaskari SA, Lee SS. Cardiac and renal changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol. 2006;12:837–42.PubMed
7.
go back to reference Kayali Z, Herring J, Baron P, et al. Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gasteroenterol Hepatol. 2009;24:1030–7.CrossRef Kayali Z, Herring J, Baron P, et al. Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gasteroenterol Hepatol. 2009;24:1030–7.CrossRef
8.
go back to reference Arroyo V, Ginès P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–76.PubMedCrossRef Arroyo V, Ginès P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–76.PubMedCrossRef
9.
go back to reference Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;46:935–46.PubMedCrossRef Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;46:935–46.PubMedCrossRef
10.
go back to reference Lin PH, Aickin M, Champagne C, et al. Food group sources of nutrients in the dietary patterns of the DASH-Sodium trial. J Am Diet Assoc. 2003;103:488–96.PubMed Lin PH, Aickin M, Champagne C, et al. Food group sources of nutrients in the dietary patterns of the DASH-Sodium trial. J Am Diet Assoc. 2003;103:488–96.PubMed
11.
go back to reference Wang J, Brown MA, Tam SH, Chan MC, Whitworth JA. Effects of diet on measurement of nitric oxide metabolites. Clin Exp Pharmacol Physiol. 1997;24:418–20.PubMedCrossRef Wang J, Brown MA, Tam SH, Chan MC, Whitworth JA. Effects of diet on measurement of nitric oxide metabolites. Clin Exp Pharmacol Physiol. 1997;24:418–20.PubMedCrossRef
12.
go back to reference Ayers NA, Kapás L, Krueger JM. Circadian variation of nitric oxide synthase activity and cytosolic protein levels in rat brain. Brain Res. 1996;707:127–30.PubMedCrossRef Ayers NA, Kapás L, Krueger JM. Circadian variation of nitric oxide synthase activity and cytosolic protein levels in rat brain. Brain Res. 1996;707:127–30.PubMedCrossRef
13.
go back to reference Grisham MB, Johnson GG, Lancaster JR Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol. 1996;268:237–46. Grisham MB, Johnson GG, Lancaster JR Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol. 1996;268:237–46.
15.
go back to reference Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–47.PubMedCrossRef Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–47.PubMedCrossRef
16.
go back to reference Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18:1139–43.PubMedCrossRef Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18:1139–43.PubMedCrossRef
18.
go back to reference Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776–8.PubMedCrossRef Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776–8.PubMedCrossRef
19.
go back to reference Wink DA, Kasprzak KS, Maragos CM, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 1991;254:1001–3.PubMedCrossRef Wink DA, Kasprzak KS, Maragos CM, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 1991;254:1001–3.PubMedCrossRef
20.
go back to reference Heller J, Kristeleit H, Brensing KA, Woitas RP, Spengler U, Sauerbruch T. Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand J Gastroenterol. 1999;34:297–302.PubMedCrossRef Heller J, Kristeleit H, Brensing KA, Woitas RP, Spengler U, Sauerbruch T. Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand J Gastroenterol. 1999;34:297–302.PubMedCrossRef
21.
go back to reference Payabvash S, Ghahremani MH, Goliaei A, et al. Nitric oxide modulates glutathione synthesis during endotoxemia. Ree Radic Biol Med. 2006;41:1817–28.CrossRef Payabvash S, Ghahremani MH, Goliaei A, et al. Nitric oxide modulates glutathione synthesis during endotoxemia. Ree Radic Biol Med. 2006;41:1817–28.CrossRef
22.
go back to reference Türkay C, Yönem O, Arikan O, Baskin E. Nitric oxide and renal functions in liver cirrhosis. Turk J Gastroenterol. 2004;15:73–6.PubMed Türkay C, Yönem O, Arikan O, Baskin E. Nitric oxide and renal functions in liver cirrhosis. Turk J Gastroenterol. 2004;15:73–6.PubMed
23.
go back to reference Elsing C, Harenberg S, Stremmel W, Herrmann T. Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients. World J Gastroenterol. 2007;13:421–5.PubMed Elsing C, Harenberg S, Stremmel W, Herrmann T. Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients. World J Gastroenterol. 2007;13:421–5.PubMed
24.
go back to reference Arkenau HT, Stichtenoth DO, Frölich JC, Manns MP, Böker KH. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol. 2002;40:907–13.PubMedCrossRef Arkenau HT, Stichtenoth DO, Frölich JC, Manns MP, Böker KH. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol. 2002;40:907–13.PubMedCrossRef
25.
go back to reference Hassan MI, Kassim SK, Ali HS, Sayed E-DA, Khalifa A. Evaluation of nitric oxide (NO) levels in hepatitis C virus (HCV) infection: relationship to schistosomiasis and liver cirrhosis among Egyptian patients. Dis Markers. 2002;18:137–42.PubMedCentralPubMedCrossRef Hassan MI, Kassim SK, Ali HS, Sayed E-DA, Khalifa A. Evaluation of nitric oxide (NO) levels in hepatitis C virus (HCV) infection: relationship to schistosomiasis and liver cirrhosis among Egyptian patients. Dis Markers. 2002;18:137–42.PubMedCentralPubMedCrossRef
26.
go back to reference Moustafa AH, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med. 2009;20:703–8.PubMedCrossRef Moustafa AH, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med. 2009;20:703–8.PubMedCrossRef
27.
go back to reference Abdallahi OM, Bensalem H, Diagana M, De Reggi M, Gharib B. Inhibition of nitric oxide synthase activity reduces liver injury in murine schistosomiasis. Parasitology. 2001;122:309–15.PubMedCrossRef Abdallahi OM, Bensalem H, Diagana M, De Reggi M, Gharib B. Inhibition of nitric oxide synthase activity reduces liver injury in murine schistosomiasis. Parasitology. 2001;122:309–15.PubMedCrossRef
28.
go back to reference Campillo B, Bories PN, Benvenuti C, Dupeyron C. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J Hepatol. 1996;24:707–14.CrossRef Campillo B, Bories PN, Benvenuti C, Dupeyron C. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J Hepatol. 1996;24:707–14.CrossRef
29.
go back to reference Nickovic V, Kocic G, Bjelakovic G, et al. Diagnostic significance of nitrates and nitrites and L-arginine, in development of hepatorenal syndrome in patients with end stage alcoholic liver cirrhosis. Ren Fail. 2013;35:633–9.PubMedCrossRef Nickovic V, Kocic G, Bjelakovic G, et al. Diagnostic significance of nitrates and nitrites and L-arginine, in development of hepatorenal syndrome in patients with end stage alcoholic liver cirrhosis. Ren Fail. 2013;35:633–9.PubMedCrossRef
30.
go back to reference Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol. 2006;44:209–16.PubMedCrossRef Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol. 2006;44:209–16.PubMedCrossRef
31.
go back to reference Angeli P, Wong F, Watson H, Ginès P, CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–42.PubMedCrossRef Angeli P, Wong F, Watson H, Ginès P, CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–42.PubMedCrossRef
32.
go back to reference Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012;27:34–41.PubMedCrossRef Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012;27:34–41.PubMedCrossRef
Metadata
Title
Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis?
Authors
Waheed Abdelmonsef Mahmoud
Nadia Abdelaaty Abdelkader
Amal Mansor
Publication date
01-05-2014
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 3/2014
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-013-0427-x

Other articles of this Issue 3/2014

Indian Journal of Gastroenterology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.